By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Xytis Pharmaceuticals Ltd. 

116 Gloucester Place

London    W1U 6HZ   United Kingdom
Phone: n/a Fax:



Company News
Xytis Pharmaceuticals Ltd. to Initiate First-In-Class Phase I Clinical Trials with Alpha 7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator XY4083 11/18/2008 8:23:38 AM
Xytis Names Gordon H. Busenbark as Chief Financial Officer 10/19/2007 8:57:20 AM
Xytis Pharmaceuticals Ltd. Enrolls First Patient in Phase II Clinical Study With Anatibant (XY2405) for Traumatic Brain Injury 3/13/2007 10:22:24 AM
Xytis Pharmaceuticals Ltd. Begins Phase II Clinical Study With Anatibant (XY2405) For Traumatic Brain Injury 1/9/2007 9:38:43 AM
Xytis Pharmaceuticals Ltd. Names Dr. Vincent F. Simmon President, Chief Executive Officer And Director 1/5/2007 11:34:37 AM
Xytis Inc. Raises $24.5 Million In Series B Financing; Proceeds To Conduct Phase II/III Clinical Trials In Traumatic Brain Injury; Phase I/II In Schizophrenia 1/9/2006 10:52:42 AM
Fournier Pharma And Xytis Pharmaceuticals Ltd. Announces Agreement For Development And Commercialisation Of Anatibant10/19/2005 5:08:55 PM